miGut-Health at ECCO 2026

miGut - Health project partners were strongly represented at this year’s Congress of the European Crohn’s and Colitis Organisation (ECCO), held from 18–21 February 2026. As one of the leading global events in inflammatory bowel disease (IBD), the ECCO Congress brings together clinicians, researchers, industry representatives and patient organisations to discuss the latest scientific advances and therapeutic strategies in Crohn’s disease and ulcerative colitis.

Throughout the Industry, Scientific, Educational and Poster programmes, miGut-Health partners highlighted progress in precision medicine, biomarker discovery, immune profiling, microbiome research and long-term disease management.

In the Industry Programme, Stefan Schreiber (IKMB) and Jonas Halfvarson (Örebro University) addressed key therapeutic developments, including remission strategies in the IL-23 era, long-term outcomes in IBD and disease modification in ulcerative colitis and the evolving role of JAK inhibitors. Nutritional strategies were also featured, with research on combining enteral nutrition with biologics in Crohn’s disease.

Within the Scientific Programme, partners presented major studies and research on predictive protein signatures in newly diagnosed ulcerative colitis, presented by Olle Grännö (Örebro University). Johan Burisch (Hvidovre Hospital) chaired a session on Fundamental and Translational Science in IBD where Hesham ElAbd (IKMB) presented his abstract “T cell receptor alpha repertoire profiling reveals a distinct immune landscape in primary sclerosing cholangitis compared with inflammatory bowel disease.”

The International Federation of Crohn’s and Ulcerative Colitis Associations was present with its booth in the exhibition area, actively engaging with the global IBD community. IFCCA also presented a poster on the Engage IBD Guide, developed within miGut-Health to empower patients through accessible, personalised and evidence-based information. This strong patient-centred presence highlighted the project’s commitment not only to scientific excellence, but also to meaningful patient involvement and impact.

A broad range of posters further showcased collaborative research across Europe, spanning microbiome-host interactions, metabolomics, immune mechanisms, disease monitoring tools, fibrosis risk, and patient-centred innovation.

The strong presence of miGut-Health partners at ECCO 2026 once again demonstrates the project’s active role in shaping the future of precision medicine in IBD and improving long-term outcomes for people living with these chronic conditions.

miGut - Health acknowledgement posters:

• P0161: From health engagement to prevention: Co-development and optimisation of a personalised patient guide to empower self-management in inflammatory bowel disease D. Usta, A. Costa Pereira,, M. Acampora, M. Savarese, M.S. De Rocchis,, L. Avedano, G. Graffigna
• P0173: High throughput profiling of the B cell repertoire identifies systematic changes in the repertoire of individuals with Crohn’s disease A. Mahdy, Z. Taheri, M. Høivik, A. Franke, H. ElAbd
• P0012: Microbial tryptophan metabolites differentially modulate epithelial responses in Crohn’s disease and non-IBD intestinal organoids R. Inčiūraitė, M. Wobbe, G. Paškevičiūtė, V. Kiudelis, J. Kupčinskas, P. Rosenstiel, J. Skieceviciene
• P0071: Faecal Microbiota Transplantation from Collagenous Colitis Patients Failed to Induce Inflammation in Mice V. Kiudelis, J. Mingaila, I. Karaliute, G. Alzbutas, H. Elabd, A. Burokas, G. Kiudelis, J. Skieceviciene, J. Kupčinskas
• P0229: Bowel urgency across inflammatory bowel disease phenotypes:A large real-world analysis reveals high symptom burden in ileal Crohn’s disease F. Tran, M. Bourgery, N.N. Eicker, F. Hinrichsen, M. Guggeis, L. Welz, B. Schreiweis, K. Aden, P. Rosenstiel, S.W. Schreiber
• P0422: Type I and II interferon blood signatures correlate with ultrasound markers of intestinal fibrostenosis and predict surgical outcomes in Crohn’s disease F. Nasehi, L. Blömer, N. Mishra, F. Kimmig, J. P. Bernardes, M. Bourgery, C.M. Wolff, F. Hinrichsen, M. Guggeis, S. Nikolaus, W. Lieb, A. Franke, K. Aden, S.W. Schreiber, P. Rosenstiel, F. Tran
• P1320: Longitudinal metagenomic profiling reveals early microbial changes during infliximab response in IBD V.A. Lopez Agudelo, F. Tran, M. Florea, M. Wiestler, M. Rühlemann, L. Moitinho E Silva, M. Groussin, S. Waschina, E.M. Wacker, R. Meneses, C. Verspecht, I. Reniers, D. Ekhlas, J. Raes, S. Huber, U. Seidler, K. Aden, S.W. Schreiber, P. Rosenstiel
• P1328: Systematic screening of tryptophan metabolism identifies site- and microbial-specific signatures of tryptophan utilization in experimental colitis L. Welz, A. Alsaadi, D. Harris, M. Yu, T. Mekdoud, J. Bornhäuser, E. Springer, C. Gilloteau, A. Pothakamury, J. Smith, B. Jenkins, F. Sommer, S. Waschina, P. Rosenstiel, S.W. Schreiber, M. McReynolds, K. Aden
• P0858: Intestinal Ultrasound in Monitoring and Predicting Outcomes in Ulcerative Colitis - A Systematic Review S. Josefsen, T. Larsen, R.L. Wilkens, J.B. Seidelin, J. Burisch, M. Attauabi, J.T. Wium Bjerrum
• P1122: Infliximab infusion reactions in Immune Checkpoint Inhibitor Colitis: a comparative study with Inflammatory Bowel Disease P.D. Ovesen, E. Dahl, M. Zhao, A. Poulsen, J. Burisch, C. Steenholdt, J.B. Seidelin
• P0088: The exposome metabolome in paediatric inflammatory bowel disease: A cross-sectional study in a population-based Norwegian cohort B. Salomon, S. Salihovic, C. Bache-Wiig Mathisen, S. Andersen, C. Olbjørn, G. Perminow, V. Kristensen, O. Grännö, D. Bergemalm, R. Kruse, D. Repsilber, M. Orešič, T. Hyötyläinen, M. Høivik, J. Halfvarson
• P0247: A proximity extension assay-based serum assay enabling absolute quantification of prognostic proteins in inflammatory bowel disease: Development and Analytical Validation A. Germanopoulos, D. Bergemalm, O. Grännö, B. Salomon, C. Eriksson, R. Kruse, C.R. Hedin, M. Carlson, M. Rejller, D. Füchtbauer, L. Davíðsdóttir, A. Fejrskov, V.C. Andersen, C. Bache-Wiig Mathisen, M.B. Bengtson, T.B. Aabrekk, T.E. Detlie, R. Opheim, V. Kristensen, S. Salihovic, L. Öhman, J.D. Söderholm, C.M. Lindqvist, J. Jahnsen, J. Satsangi, R. Kalla, F. Gomollón Garcia, P. Ricanek, M. D'Amato, J. Kjeldsen, M. Høivik, D. Repsilber, J. Halfvarson
• P0510: Non-targeted lipidomic profiling reveals distinct molecular signatures in inflammatory bowel disease: Discovery and validation in two inception cohorts S. Salihovic, O. Øyås, S. Hyll Hansen, B. Salomon, D. Bergemalm, H. Hjortswang, O. Grännö, C.R. Hedin, C. Eriksson, K. Holm, T.B. Aabrekk, M. D'Amato, M. Orešič, T.E. Detlie, V. Kristensen, Å. Keita, C.M. Lindqvist, L. Öhman, M. Carlson, J.D. Söderholm, D. Repsilber, R. Kruse, J.E.R. Hov, T. Hyötyläinen, M. Høivik, J. Halfvarson
• P0744: Early colectomy and long-term risk of cardiometabolic disease in Ulcerative Colitis: A nationwide cohort study A. Faye, B. Kochar, J. Axelrad, J. Sun, C. Nordenvall, J. Halfvarson, O. Olen, J. Soderling, J. Ludvigsson
• P1259: Risk factors for intestinal fibrosis on mucosal biopsies in patients with inflammatory bowel disease in Sweden: a cohort study J. Sun, M. Li, B. Roelstraete, F. Rieder, G. Veress, E. Osagie-Igho, G. Lawlor, D. Bergman, J. Halfvarson, O. Olen, G. Liu, J. Ludvigsson7
• P0125: Enhanced fecal protease activity in inflammatory bowel diseases is driven by human proteases and is effectively inhibited by protease inhibitors isolated from potato L. Herreman, R. Gacesa, P. Pibiri, B.H. Jansen, J. Vandooren, P. Horvatovich, M.C. Laus, G. Dijkstra, K.N. Faber
• P0224: Blood-based biomarkers of gut barrier integrity associate with disease activity and future disease progression in inflammatory bowel disease S. Geertsema, A.R. Bourgonje, F. Veenstra, R. Gacesa, R.R. Fagundes, L. Spekhorst, S. Hu, S. de Jong, B.H. Jansen, H. Holstein, D. Ruane, A.K. Kannan, R.K. Weersma, H. van Goor, G. Dijkstra, K.N. Faber
• P0487: Elevated Serum Glutathione and Ischemia Modified Albumin Reflect Active Endoscopic Disease in Inflammatory Bowel Disease S. Geertsema, H. Holstein, M.L.C. Bulthuis, S. de Jong, M. Reinders-Luinge, K. Koerts-Steijn, A. Muller Kobold, K.N. Faber, H. van Goor, G. Dijkstra, A.R. Bourgonje
• P0003: Linking cholesterol homeostasis to intestinal inflammation in inflammatory bowel diseases H. Molina, J. Astorga, V.A. Lopez, K. Dubois-Camacho, G. Landskron, M. De la Fuente, R. Fernandez, L. Flores, E. Festen, K.N. Faber, G. Dijkstra, R.K. Weersma, M. Lui, P. Nuñez, R.E. Quera, M. Hermoso

Hesham ElAbd (IKMB) presenting

Rūta Inčiūraitė (LSMU)

Jonas Halfvarson (Örebro University)

Maria Stella De Rocchis (IFCCA)

ENGAGE-IBD Personalized Health Engagement Guide